Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853658 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,064
- Enrollment target
NCT00853658 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 7,064 participants.
The verdict
NCT00853658, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,064 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.
Interventions
- DRUG Aliskiren
- DRUG Enalapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,064 participants |
| Start Date | 2009-03 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853658
The ClinicalTrials.gov registry entry for NCT00853658 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,064 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aliskiren is the first listed.
NCT00853658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00853658 about?
NCT00853658 is a clinical study titled "Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure". The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.
What is the current status of trial NCT00853658?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,064 participants. The study started on 2009-03. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00853658?
The interventions under investigation include: Aliskiren (DRUG), Enalapril (DRUG).
Who is sponsoring clinical trial NCT00853658?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.